techMARK (TASX)

5,635.17
   
  • Change Today:
      23.98
  • 52 Week High: 5,661.11
  • 52 Week Low: 4,135.10

Latest ShareCast News

GSK's COPD treatment approved by Chinese regulators

By Benjamin Chiou

Date: Monday 05 Jan 2026

(Sharecast News) - Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD).

techMARK Regulatory News

Form 8.3 - NCC Group plc 05-Jan-2026 12:03 RNS
Form 8.5 (EPT/RI) NCC Group PLC 05-Jan-2026 12:00 RNS
Form 8.3 NCC Group Plc 05-Jan-2026 11:11 RNS
Nucala for adults with COPD approved in China 05-Jan-2026 07:00 RNS
Transaction in Own Shares 05-Jan-2026 07:00 RNS

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Price Data

Price 5,635.17
Change Today 23.98
% Change 0.43 %
02-Jan-26 Close 5,611.19

Top Risers

Price Change
BA. 1,841.50p +5.0%
QQ. 457.00p +2.8%
XPP 918.00p +2.7%
CCC 2,982.00p +2.1%
OXB 662.00p +1.1%
FLTR 16,190.00p +0.4%
VOD 99.52p +0.3%
XAR 102.00p +0.0%
RM. 114.00p +0.0%

Top Fallers

Price Change
BT.A 179.80p -2.1%
TRD 255.00p -1.9%
NCC 133.20p -0.9%
DIA 344.00p -0.9%
GNS 2,530.00p -0.6%
RSW 3,530.00p -0.6%
SN. 1,211.00p -0.5%
OXIG 2,045.00p -0.5%
GSK 1,824.50p -0.4%
SGE 1,046.50p -0.3%

Top of Page